Abstract
We present a case of toxic hepatitis related to infliximab treatment in a 38-year-old woman with rheumatoid arthritis (RA). The patient had previously been treated with different disease-modifying drugs (DMARDs) alone or in combination but had never revealed signs of liver dysfunction. Due to high disease activity, treatment with infliximab (3 mg/kg i.v.) was initiated in combination with methotrexate (MTX) (25 mg/week) and folic acid (5 mg/week). The patient stopped MTX and folic acid on her own initiative after 3 weeks due to improvement of joint symptoms. After seven infusions, progressive elevations of the transaminases up to five times the upper normal limit were noted and treatment with infliximab was terminated. Serological tests for viral and autoimmune hepatitis and for ANA and anti-dsDNA were all negative. Specific infliximab antibodies could not be detected. Ultrasound of the liver was normal. Liver biopsy showed late signs of acute toxic hepatitis without MTX-related fibrosis. This is one the first cases that convincingly demonstrates that infliximab treatment may cause toxic hepatitis. Moreover, the case suggests a lack of hepatic cross-toxicity between infliximab and etanercept as the patient continued with etanercept without new episodes of liver dysfunction.
Similar content being viewed by others
References
Heiberg MS, Koldingsnes W, Mikkelsen K et al (2008) The comparative performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthrtis Rheum 59:234–240
Behm BW, Bickston SJ (2008) Tumor necrosis factor-alfa antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 23:CD006893
Alonso-Ruiz A, Pijoan JI, Ansuategui E et al (2008) Tumor necrosis factor alpha drugs in rheumatois arthritis: systematic review and metaanalysis of efficacy and safety. BMC Muskuloskelet Disord 9:52
Ostuni P, Botsios C, Punzi L et al (2003) Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 62:686–687
Wendling D, Auge B, Bettinger D et al (2005) Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 64:788–789
Germano V, Diamanti AP, Baccano G et al (2005) Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 64:1519–1520
Soto-Fernandez S, Gonzalez-Carro P, De Pedro-Esteban A et al (2006) Infliximab-induced hepatitis in a patient with Crohn's disease. Gastroenterol Hepatol 29:321–322
Wahie S, Alexandroff A, Reynolds NJ (2006) Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis. Clin Exp Dermatol 31:460–461
Marques M, Magro F, Cardoso H et al (2007) Infliximab-induced lupus like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis 14:723–725
Hansen KE, Hildebrand JP, Genovese MC et al (2004) The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 31(6):1098–1102
Thiéfin G, Morelet A, Heurgué A et al (2008) Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine 75:737–739
García Aparicio AM, Rey JR, Sanz AH et al (2007) Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol 26:811–813
Feletar M, Brockbank JE, Schentag CT et al (2004) Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 63:156–161
Provenzano G (2004) Liver toxicity of infliximab in psoriatic arthritis. Ann Rheum Dis June 24: e-letter
Disclosures
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Carlsen, K.M., Riis, L. & Madsen, O.R. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol 28, 1001–1003 (2009). https://doi.org/10.1007/s10067-009-1179-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-009-1179-y